4P
4D Path
United States · Healthtech · Biotech · AI · Enterprise software
Digital biomarkers designed to predict cancer treatment response from routine biopsy images.
Reading tumour dynamics from pathology slides
4D Path’s Q-Plasia OncoReader platform analyzes digitized H&E-stained biopsy images. Its physics-informed approach quantifies cell-cycle changes and features of the tumour microenvironment to generate treatment-response signatures.
The cloud-based workflow produces predictive reports for clinical research and drug-development partnerships. It supports work such as selecting trial cohorts and studying resistance to treatment across different cancers and therapies.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Strategic | Undisclosed | Participants not disclosed |